Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2

Simone Bastrup Israelsen; Anton Pottegård; Håkon Sandholdt; Sten Madsbad; Reimar Wernich Thomsen; Thomas Benfield

doi:10.1111/dom.14329

Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2

Simone Bastrup Israelsen, Anton Pottegård, Håkon Sandholdt, Sten Madsbad, Reimar Wernich Thomsen, Thomas Benfield

Research output: Contribution to journal › Letter › Research › peer-review

49 Citations (Scopus)

Original language	English
Journal	Diabetes, Obesity and Metabolism
Volume	23
Issue number	6
Pages (from-to)	1397-1401
Number of pages	5
ISSN	1462-8902
DOIs	https://doi.org/10.1111/dom.14329
Publication status	Published - 1 Jun 2021

Access to Document

10.1111/dom.14329Licence: Other

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014019/pdf/DOM-23-1397.pdfLicence: Other

Cite this

Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. / Israelsen, Simone Bastrup; Pottegård, Anton; Sandholdt, Håkon; Madsbad, Sten; Thomsen, Reimar Wernich; Benfield, Thomas.

In: Diabetes, Obesity and Metabolism, Vol. 23, No. 6, 01.06.2021, p. 1397-1401.

Research output: Contribution to journal › Letter › Research › peer-review

Israelsen, Simone Bastrup ; Pottegård, Anton ; Sandholdt, Håkon ; Madsbad, Sten ; Thomsen, Reimar Wernich ; Benfield, Thomas. / Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. In: Diabetes, Obesity and Metabolism. 2021 ; Vol. 23, No. 6. pp. 1397-1401.

@article{a48f65d7abd24fe89c04204803d9b62a,

title = "Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2",

author = "Israelsen, {Simone Bastrup} and Anton Potteg{\aa}rd and H{\aa}kon Sandholdt and Sten Madsbad and Thomsen, {Reimar Wernich} and Thomas Benfield",

year = "2021",

month = jun,

day = "1",

doi = "10.1111/dom.14329",

language = "English",

volume = "23",

pages = "1397--1401",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2

AU - Israelsen, Simone Bastrup

AU - Pottegård, Anton

AU - Sandholdt, Håkon

AU - Madsbad, Sten

AU - Thomsen, Reimar Wernich

AU - Benfield, Thomas

PY - 2021/6/1

Y1 - 2021/6/1

U2 - 10.1111/dom.14329

DO - 10.1111/dom.14329

M3 - Letter

C2 - 33502076

VL - 23

SP - 1397

EP - 1401

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 6

ER -